cyrilzakka/clinical-trials huggingface dataset:
Chinese Community Sample of Hierarchical Model of Psychopathology

By validating Hierarchy Model of psychopathology(HiTOP) in Chinese community samples, this study aims for illumating the problem of diagnostic heterogeneity and high comorbidity within existing psychiatric classification systems in Chinese culture. Concurrently, this study also focuses on exploring trans-diagonostic risk and proctective factors underline HiTOP dimensions.

the main questions it aims to answer are:

1. Explore HiTOP model cultural differences between western culture and eastern culture.
2. Understand the impact of different dimension of adverse childhood experience on HiTOP structure.
3. Investigate the relationship between individual unique psychological variables and psychopathological dimensions.

Participants will receive a detailed survey trying to measure their psychopathology symptoms, adverse childhood experience and psychological variables. This study expects to fallow up participants for 4 years to monitor the symptom changes.


Eligibility Criteria:
Inclusion Criteria:

1. Chinese citizens
2. Years of education \> =9 years.
3. age \>= 18 years old.

Exclusion Criteria:

(1)Subjects who have insufficient self-awareness, and are unable to obtain complete informed consent, such as: schizophrenia, manic episode of bipolar disorder, severe depression.
Caring Light Project for Family Caregivers

Caring Light is designed to help caregivers of someone with Alzheimer's Disease and related dementia to cope with the difficulties related to caregiving, reduce stress, and improve quality of life.

The goals of this study are to evaluate materials related to dementia caregiving and how to cope with difficult situations faced by caregivers. Based on this research, the investigators are developing the new Caring Light mobile app with a self-paced program to enhance the quality of life, a curriculum that incorporates relaxation techniques, and coping skills training.

Eligibility Criteria:
Inclusion Criteria:

* Care for an individual with Alzheimer's Disease or other dementia.
* Own a smartphone or tablet and have Internet access.
* Minimum age of 18 years old.
* Spend at least 8 hours/week caring for a person with dementia.

Exclusion Criteria:

* Severe psychological or physical illness.
* Inability to read and follow English instructions.
* High level of depressive symptoms.
* Unwillingness to participate in all aspects of the study.
Adherence to Physiotherapy Scoliosis Specific Exercises in Adolescents With Spine Deformity: Development of a New Questionnaire

This study aims to develop a new instrument capable of providing an efficient measure of the quality and quantity of adherence to Physiotherapy Scoliosis Specific Exercises performed at home by growing patients with spinal deformity undergoing conservative treatment at a specialized institution. The development of a questionnaire in a Rasch environment and specifically developed for this population will ensure greater sensitivity and specificity of the questionnaire.


Eligibility Criteria:
Inclusion Criteria:

* aged between 10 and 18 years
* adolescent idiopathic scoliosis of 10 ° Cobb or more
* Scheuermann's kyphosis or idiopathic hyperkyphosis
* prescription of specific exercises

Exclusion Criteria:

* positive neurological evaluation
A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Metformin

The purpose of this study is to assess the effect of multiple doses of isavuconazole on the pharmacokinetics of a single dose of metformin. Safety and tolerability of isavuconazole will be assessed alone and in combination with metformin.

Subjects will check-in to the clinic on Day -1 and remain confined through completion of the study procedures on Day 10.

A follow-up telephone call will be made on Day 16 to check on health status.

Eligibility Criteria:
Inclusion Criteria:

* The subject has a body weight of at least 45 kg and a body mass index of 18 to 32 kg/m2, inclusive.
* QTcF must be 360 to 430 msec for males and 370 to 450 msec for females
* Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and serum creatinine must not be above the normal range.
* Female subject is of non-childbearing potential or if of childbearing potential must use highly effective birth control from Screening through 28 days after the end of the study. Females must not be breastfeeding or donate ova from Screening through 20 days after the end of the study.
* Male subject must be using highly effective contraception from Screening through 90 days after final study drug administration. Male subject must not donate sperm starting at Screening through 90 days after final study drug administration.

Exclusion Criteria:

* The subject has a history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmia or torsade de pointes, structural heart disease, or family history of either Short or Long QT syndrome (suggested by sudden death of a close relative at a young age due to possible or probable cardiac causes).
* The subject has a positive result for hepatitis B surface antigen, hepatitis C antibodies at Screening or is known to be positive for human immunodeficiency virus.
* The subject has a known or suspected allergy to any of the components of the trial products or the azole class of compounds, or a history of multiple and/or severe allergies to drugs or foods, or a history of severe anaphylactic reactions.
* The subject is a smoker (any use of tobacco or nicotine containing products) in the last 6 months.
* The subject has had treatment with any prescribed or non-prescribed drugs in the 2 weeks prior to Day 1, with the exception of occasional use of acetaminophen up to 2 g/day.
* The subject has participated in any interventional clinical study or has received any investigational drugs within 30 days or 5 half-lives, whichever is longer, prior to Screening.
* The subject has participated in a prior study with isavuconazole.
* The subject has history of consuming more than 14 units of alcoholic beverages per week within 6 months prior to screening or has a history of alcoholism or drug/chemical/substance abuse within past 2 years prior to screening or the subject tests positive at screening or Day -1 for alcohol or drugs of abuse.
* The subject is an employee of the Astellas Group or vendors involved in the study.
A Study of Evacetrapib and Rifampin in Healthy Participants

The main purpose of this study is to determine how much evacetrapib gets into the blood stream and how long it takes the body to get rid of it when given with rifampin. The safety and tolerability of the two drugs, given together, will also be evaluated. The study will also look at blood cholesterol levels and levels of a hormone called cortisol before and after taking rifampin. Information about any side effects that may occur will also be collected.

For each participant, this study will include 2 periods in fixed order. The study will last approximately 29 days.


Eligibility Criteria:
Inclusion Criteria:

* Overtly healthy males and females (of non child-bearing potential)
* Have a body mass index of 18 to 32 kilograms per square meter (kg/m\^2), inclusive, at screening

Exclusion Criteria:

* Have known allergies to evacetrapib, rifampin, related compounds or any components of either formulation, or history of significant allergic disease as determined by the investigator
Message Encouraging Vaccination in Preparation for the Holidays

This experiment is part of a megastudy with a total of ten experimental conditions and a holdout control condition to which patients will be randomly assigned. Ther focal comparison in this experiment is between a message encouraging vaccination by reminding participants that the holiday season is just a few weeks away and getting vaccinated will allow them to more safely gather with loved ones and a control message telling patients that an updated COVID booster vaccine is waiting for them. The intervention testing if text messages encouraging vaccination by reminding participants that the holiday season is just a few weeks away and getting vaccinated will allow them to more safely gather with loved ones will produce more vaccinations than otherwise identical messages.


Eligibility Criteria:
Exclusion Criteria:

1. The patient unsubscribed from texts before the send date and time of the patient's SMS/MMS message
2. The patient received a bivalent COVID booster before the send date and time of the patient's SMS/MMS message.
A Prospective Study Comparing the Mifne Approach of Treating Childhood Autism With Routine Standard Treatment

The current study aims at comparing outcomes achieved using the Mifne approach of treating autistic children with results obtained when routine standard treatment is used. A prospective comparative study will be performed comparing the results of 12 children treated at Mifne with 12 children treated with treatment as usual. A child and adolescent psychiatrist using the Autism Diagnostic Interview-Revised (ADI-R) and the Autism Diagnostic Observation Schedule-Generic (ADOS-G) will make the diagnostic assessment and a developmental psychologist will make the developmental and psychological assessments using the Vineland Adaptive Behavior Scales-Revised and the Bayley Scales of Infant Development (BSID II) before the child enters the study. Each child will be reassessed following completion of the Mifne intervention, at three and at six months after commencement of treatment. The control child will also be reassessed at three and at six months after commencement of a therapeutic intervention.


Eligibility Criteria:
Inclusion Criteria:

* All children between the ages of 2-5 years who meet diagnostic criteria for Autism or Pervasive Developmental Disorder by DSM IV criteria who are referred for treatment at Mifne for the treatment group.
* The control group will consist of children meeting the same criteria who are referred to Schneider Children's Medical Center of Israel (SCMCI). Matching will be for age, sex, ethnicity, socioeconomic status, IQ, language development and diagnosis.

Exclusion criteria:

* All referred children who do not meet criteria for Autism or PDD or do not understand Hebrew.
Effect of Mobilization Protocol on Mobilization

The aim of this study is to determine the effect of early mobilization protocol on patients' mobilization status and patient care outcomes in patients who undergo major abdominal surgery. This study is a prospective non-randomized controlled clinical trial.

The study sample consisted of 42 patients, 21 of whom were the control group and 21 were the intervention group, who had undergone major abdominal open surgery between May and September 2019. The routine mobilization follow-up approach of the intensive care unit was applied to the patients in the control group, and the early mobilization protocol developed by using up-to-date guidelines and expert opinions were applied to the patients in the intervention group. In the study, the data of the control group were firstly collected, then the early mobilization protocol was introduced to the patients through the training brochure prepared and then data of the intervention group were collected. In the study, the characteristics of the patients in both groups belonging to the preoperative period, the distance they walked in the 6-minute walking test and the results of the postoperative period were recorded.

Eligibility Criteria:
Inclusion Criteria:

* To undergo major abdominal open surgery
* ASA \<IV
* Being over the age of 18
* Not having a barrier to communication
* Having agreed to participate in the study

Exclusion Criteria:

* Being diagnosed that may limit mobilization
* Being diagnosed with chronic obstructive pulmonary disease
* ASA IV-V-VI
A Computer-based Intervention to Augment Home Visitation Services: The E-Parenting Project

The current protocol aims to examine the effects of a computer-based intervention used in conjunction with existing Healthy Families America (HFA) home visitation programs on the challenges related to participant enrollment, retention, and motivation as well as parent and child outcomes.

The present study aims to determine whether a computer-based intervention can provide augmentation of home visiting services to decrease the risk of child maltreatment. The computer-based software includes modules on motivation, Cognitive Retraining, and elements of the ecobehavioral SafeCare approach. A total of 420 mother-infant dyads from four Healthy Families America (HFA) sites will be randomly assigned to either treatment as usual, software-supplemented home visitation, or community control conditions. For families in the software-supplemented condition, home visitors will present the software to parents via a Tablet PC during regular home visits. All parents will be followed-up at 6, 12, and 18 months by independent and blinded research assistants. Parents are evaluated for maltreatment and maltreatment risks as measured by self-report, home visitor report, blinded independent observers, and statewide CPS data. If validated, the proposed intervention can provide augmentation of home visiting services with unprecedented ease of dissemination, at negligible additional cost, and with limitless potential for further development.

Eligibility Criteria:
Inclusion Criteria:

Pregnant or post-partum mothers who are eligible (i.e., score 25 or greater on the Kempe Family Stress Checklist and are not involved in CPS open case investigation at the time of HFA participation) and willing to participate in the HFA program are eligible to participate in the current study, with the following restrictions:

1. Mothers must be 18 years or older and able to complete the baseline assessment within 4 weeks of delivery.
2. Mothers have not completed any prior post-partum treatment plan.
3. Participants must have functional cognitive abilities.
4. Premature infants have to be released from hospital care within 6 weeks of birth.
5. Participants must be able to communicate in English.
Clinical and Health-related Outcome of rFVIIIFc Prophylaxis

Current standard therapy for patients with haemophilia (PwH) in the prevention of bleeding episodes is a prophylactic intravenous treatment with recombinant coagulation factor (F) VIII (Haemophilia A) or rather FIX (Haemophilia B) two to three times weekly. With the development of recombinant factor VIII Fc fusion protein (rFVIIIFc) the conventional routine prophylaxis regime is complemented by an extended half-life (EHL) factor replacement prophylaxis with the potential of improved bleed prevention and reduced injection frequency at similar factor consumption. Aim of this longitudinal multicentre study is to evaluate the influence of an EHL factor replacement regime with rFVIIIFc on haemophilic specific parameters (annual bleeding rate, bleeding localisation), joint status, pain, functional parameters, treatment adherence and health-related quality of life in PwH A.


Eligibility Criteria:
Inclusion Criteria:

* Patients suffering from moderate to severe haemophilia A
* Age ≥ 18-years
* Treatment with FVIII prophylaxis
* Submitted written informed consent

Exclusion Criteria:

Patients suffering from other bleeding diseases

* Patients with inhibitors
* Patients without written informed consent
* Age \< 18-year-old
* Any surgeries up to 6 months before the examination date
* Suffering from different rheumatologic diseases like M. Bechterew, Psoriasis or other local or generalized joint infections (Borreliosis, septic arthritis)
The Connection Between Areas in the Brain of Blind Patients

The purpose of this study is to test the belief that specific areas of the brain are connected differently in blind patients than patients with sight. In addition, the study will examine the different anatomical connections between brain areas of patients who became blind early in life versus patients who became blind later.

The purpose of this protocol is to test the hypothesis that the anatomical connectivity of occipital and somatosensory areas in early blind subjects differs from that in subjects who became blind later in life and from that in sighted volunteers.

Eligibility Criteria:
INCLUSION CRITERIA:

Subjects with late blindness.

Subjects with early blindness.

Sighted volunteers.

Age between 18 and 65 years.

EXCLUSION CRITERIA:

Subjects with personal or family history of seizures or other neurological or demyelinating disorders.

Pregnant women tested after urine pregnancy test.

Subjects with metal in the cranium except mouth.

Subjects with intracardiac lines and implanted medication pumps.

Subjects with increased intracranial pressure as evaluated by clinical means.

Subjects with cardiac pacemakers.

Intake or neuroleptics.

Subjects with blindness secondary to degenerative CNS diseases.
An Ultrasound Imaging Technique to Measure Tumors in People With Pancreatic Ductal Adenocarcinoma (PDAC) or Gastrointestinal (GI) Adenocarcinoma

The purpose of this study is to see if ultrasound images that are analyzed by a special computer program can be used to measure the size of PDAC tumors in the liver as accurately as CT scans that involve contrast material (also called contrast-enhanced CT scans). All participants in this study will have pancreatic ductal adenocarcinoma (PDAC) that has spread (metastasized) to the liver, and all participants will be scheduled for a routine CT scan that will measure their cancer.


Eligibility Criteria:
Inclusion Criteria:

* Male and female patients, 18 years of age or older
* Confirmed diagnosis of PDAC or GI tract adenocarcinoma metastatic to liver
* Scheduled for imaging with contrast enhanced CT

Exclusion Criteria:

* Inability to tolerate intravenous contrast medium
* All liver metastases ≤ 10 mm in maximal diameter on the contrast enhanced CT used for comparison to the planned research ultrasound
* Multiple confluent liver metastases or tumor burden \> 50% of the liver as estimated by a radiologist
Comparison of Two D-Dimers Dosing Techniques

Study of the possibility of substitution of the automated STAGO D-Dimers method with the semi-automated VIDAS method, which is more expensive, longer to implement and requires the use of a dedicated automaton.

To compare D-Dimer assay techniques in the exclusion of VTE (Thromboembolic Venous Disease):• BIOMERIEUX: D-Dimers VIDAS (considered as reference technique)• STAGO: D-Di PlusOn a population of patients recruited in Brest for a period of 1 year: patients for whom a dosage of VIDAS D-dimers is prescribed (approximately 3700 patients)

Eligibility Criteria:
Inclusion Criteria:

* Patients for whom a dosage of D-Dimers VIDAS is prescribed in the context of a suspicion of VTE at Brest CHRU.
* No opposition formulated.

Exclusion Criteria:

* Curative dose anticoagulant treatment whatever the indication,
* Pregnancy in progress,
* Follow-up at 3 months not possible,
* Patient refusing to participate
The Effect of Exercise Training Programs On Balance in Older Adults With CVD

Individuals of advanced age with cardiovascular disease are at higher risk of fall.The aim of this study is to explore the effect of specific exercise program based on balance and coordination on stability parameters


Eligibility Criteria:
Inclusion Criteria:

* Has Cardiovascular disease, under the supervision of a cardiologist
* Participates in a cardiovascular rehabilitation center
* Able to undergo physical activity for 60 minutes twice a week

Exclusion Criteria:

* All Other
Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease

Alzheimer's disease is a medical illness that damages the brain and causes problems with memory, mood and behavior. A substance called acetylcholine (ACh), which is naturally produced in the body, plays an important role in the normal functioning of the brain. In subjects with Alzheimer's disease, the level of ACh is greatly reduced. Currently, there are three commonly prescribed drugs used for treating the symptoms of Alzheimer's disease by helping to maintain the level of ACh in the brain. This study will evaluate how much each of these drugs changes the levels of certain brain chemicals that are known to, or may play an important role in, Alzheimer's disease and its symptoms.


Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of mild to moderate Alzheimer's disease
* Must be able to swallow capsule/tablet
* Must have a caregiver who is available to attend all study visits

Exclusion Criteria:

* Digestive problems related to peptic ulcer
* Experienced a heart attack or stroke in the last 6 months
* Serious/unstable asthma or severe pulmonary (lung) disease
* On current treatment with a blood thinner
Delayed Against Rapid Sequence Induction in Adults With Medical Diseases Undergoing Emergency Endotracheal Intubation.

The goal of this clinical trial is to learn if it is feaseble to conduct a superiority trial comparing two methods for endotracheal intubation in critically ill patients. It will also learn about validity of outcomes regarding endotracheal intubation. The main questions it aims to answer are:

* Does performing intubation via Delayed Sequence Induction lower the incidence of severe hemodynamic complications compared to Rapid Sequence Induction?
* How are hemodynamic complications in the severely ill to be measured in order to minimize bias?

Participants will:

* receive emergency endotracheal intubation via Delayed or Rapid Sequence induction
* receive a phone call 90 days after endotracheal intubation
* outcome parameters outside of follow up phone calls will be routinely collected during the regular ICU-stay, there won't be any additional testing


Eligibility Criteria:
Inclusion Criteria:

* Adult patients 18 years or older in need of emergency endotracheal intubation in the following 60 minutes.
* The planned operateur routinely performs endotracheal intubation in critically ill patients.

Exclusion Criteria:

* Endotracheal Intubation performed during cardiopulmonary resuscitation or during "unstable ROSC", defined as Norepinephrine or Epinephrine dose \> 0,5 µg/kgKG/min after return of spontaneous circulation.
* Participation in the study is not warranted because of increased risk for the patient or otherwise not justifiable (e.g. active oral bleeding).
* Known allergy against Ketamine, Esketamine, Midazolam or Rocuronium.
* Known contraindication against Ketamine, Esketamine Midazolam or Rocuronium.
* Known or anticipated difficult airway with indication for awake fiberoptic intubation.
* Women with known pregnancy or breastfeeding.
The Effect of Maximum Body Weight in Lifetime on the Development of Type 2 Diabetes

Hypothesis : The maximum body weight in lifetime is associated with the onset of development of type 2 diabetes.

Obesity is well recognized risk factor for type 2 diabetes. Recent studies reported that weight change, especially severe weight gain was associated with an increased risk of type 2 diabetes. The aim of this study is to investigate whether the maximum body weight of lifetime is associated with the early onset of type 2 diabetes or an increased risk of type 2 diabetes in Korean.

Eligibility Criteria:
Inclusion Criteria:

* Korean with type 2 diabetes
* Korean with confirmed IFG or IGT
* Korean with NGT

Exclusion Criteria:

* Malignancy except thyroid cancer
* Active tuberculosis